Robert Marcus
Stock Analyst at JP Morgan
(1.37)
# 3,594
Out of 5,090 analysts
22
Total ratings
47.06%
Success rate
-1.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PEN Penumbra | Maintains: Neutral | $265 → $275 | $300.66 | -8.53% | 4 | Nov 6, 2025 | |
| IART Integra LifeSciences Holdings | Upgrades: Neutral | $75 | $13.23 | +466.89% | 2 | Dec 17, 2021 | |
| BDX Becton, Dickinson and Company | Downgrades: Neutral | $265 | $193.96 | +36.63% | 10 | Aug 6, 2021 | |
| GKOS Glaukos | Downgrades: Underweight | $50 | $108.51 | -53.92% | 2 | Oct 8, 2020 | |
| TMDX TransMedics Group | Downgrades: Neutral | $15 | $136.51 | -89.01% | 2 | Oct 8, 2020 | |
| ATRC AtriCure | Maintains: Overweight | $48 → $57 | $39.86 | +43.00% | 2 | Jul 29, 2020 |
Penumbra
Nov 6, 2025
Maintains: Neutral
Price Target: $265 → $275
Current: $300.66
Upside: -8.53%
Integra LifeSciences Holdings
Dec 17, 2021
Upgrades: Neutral
Price Target: $75
Current: $13.23
Upside: +466.89%
Becton, Dickinson and Company
Aug 6, 2021
Downgrades: Neutral
Price Target: $265
Current: $193.96
Upside: +36.63%
Glaukos
Oct 8, 2020
Downgrades: Underweight
Price Target: $50
Current: $108.51
Upside: -53.92%
TransMedics Group
Oct 8, 2020
Downgrades: Neutral
Price Target: $15
Current: $136.51
Upside: -89.01%
AtriCure
Jul 29, 2020
Maintains: Overweight
Price Target: $48 → $57
Current: $39.86
Upside: +43.00%